Compare SHOO & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHOO | VERA |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | 1996 | 2021 |
| Metric | SHOO | VERA |
|---|---|---|
| Price | $31.35 | $39.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $42.43 | ★ $81.30 |
| AVG Volume (30 Days) | ★ 1.4M | 968.6K |
| Earning Date | 05-28-2026 | 05-27-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $2,534,109,000.00 | N/A |
| Revenue This Year | $12.27 | N/A |
| Revenue Next Year | $5.87 | $445.28 |
| P/E Ratio | $51.82 | ★ N/A |
| Revenue Growth | ★ 11.00 | N/A |
| 52 Week Low | $19.05 | $18.53 |
| 52 Week High | $46.88 | $56.05 |
| Indicator | SHOO | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 27.97 | 42.61 |
| Support Level | $23.21 | $19.84 |
| Resistance Level | $35.98 | $56.05 |
| Average True Range (ATR) | 1.60 | 2.29 |
| MACD | -0.24 | 0.16 |
| Stochastic Oscillator | 0.72 | 39.02 |
Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.